Interest in 5N Plus (TSX:VNP) has picked up after its Q2 2026 report showed 28% revenue growth, new space power contracts, and management commentary on margin pressure alongside efforts to keep shipment plans on track.
See our latest analysis for 5N Plus.
The recent Q2 news on 5N Plus comes against a mixed price backdrop, with the share price down 30.5% over the past month but still posting a 65.9% year to date share price return and a very large 5 year total shareholder return.
If the recent space power contracts caught your attention and you want to see what else is moving around the energy transition theme, it is worth checking out 88 nuclear energy infrastructure stocks
After a sharp pullback despite strong Q2 figures and new space power wins, 5N Plus now poses a simple question: do the current margins and acquisition ambitions still leave enough upside to justify the risk at this price?
Most Popular Narrative: 47.1% Undervalued
At a last close of CA$29.87 versus a narrative fair value of CA$56.43, the most followed view on 5N Plus points to a large valuation gap that hinges on long contract visibility and capacity plans coming through.
Rapid capacity expansion at the AZUR facility in Germany, with a 30% solar cell capacity increase realized in 2025 and a further 25% increase expected to come online in the second half of 2026, positions the company to serve demand in terrestrial renewable energy and space solar power, which directly affects revenue potential and operating leverage.
Want to see what kind of revenue path and margin profile that AZUR buildout is leaning on? The narrative leans on steady growth assumptions, firm contracts and a future earnings multiple that asks investors to think more like growth stock holders than materials stock holders. The interesting part sits in how these pieces are combined into that CA$56.43 fair value story.
Result: Fair Value of CA$56.43 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, the bullish 5N Plus story still depends on metal input costs remaining manageable and key U.S. solar customer volumes holding up after the current contract period.
Find out about the key risks to this 5N Plus narrative.
Another View on 5N Plus Using Earnings Multiples
The fair value story around 5N Plus leans heavily on long term contracts and growth forecasts. Yet on a simple earnings multiple, the stock already trades at a P/E of 30.3x compared with 23.9x for the wider North American Chemicals industry and a fair ratio estimate of 15.2x. That premium suggests less margin for error if the bullish narrative slips.
For investors who prefer simple comparison tools, this earnings based view of 5N Plus is a useful cross check on the more optimistic fair value story. It also raises the question of which reference point the market might move toward over time, the higher current multiple or the lower fair ratio estimate. See what the numbers say about this price — find out in our valuation breakdown.
Next Steps
With such a split between optimism and caution around 5N Plus, it makes sense to review the full picture quickly and decide where you stand. To see how those concerns and potential upsides balance out, take a closer look at the 3 key rewards and 1 important warning sign.
Looking for more investment ideas beyond 5N Plus?
Now that you have a clearer view on 5N Plus, do not stop there. Use the screener to uncover other opportunities that could suit your portfolio.
- Target reliable income streams by focusing on companies with stronger yields and payout records using the 6 dividend fortresses.
- Spot potential bargains before the crowd by scanning for companies that look underpriced on both quality and value through the 12 high quality undervalued stocks.
- Prioritize resilience in tougher markets by zeroing in on companies with sturdier finances through the 12 resilient stocks with low risk scores.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com